10 Biotech Stocks With The Biggest Upside

Published on December 13, 2022 at 3:52 pm by Usman Kabir in Hedge Funds, News

In this article, we discuss the 10 biotech stocks with the biggest upside. If you want to read about some more biotech stocks with the biggest upside, go directly to 5 Biotech Stocks With The Biggest Upside.

The biotechnology sector has been one of the most profitable growth spaces in the stock market over the past few years. Investors are thus always looking for potential bargains in the industry that might pay off handsomely in the coming years. Amid a macro slowdown and recession fears, these bargains are readily available at much discounted rates, but identifying winners, like Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), from amongst them is a somewhat difficult task.

Biotechnology is a branch of science that develops products by utilizing biological systems, living creatures, or elements out of them. It encompasses a wide range of fields such as biochemistry, genetics, and molecular biology. Countries like China, Japan, and India have taken favorable initiatives in the field of biotechnology in the past few years. Globally, the government activities are aimed at streamlining the medication regulatory pathway, standardizing clinical studies, and expediting the product approval processes.

In light of these favorable trends, the industry has explosive growth potential. According to a recent report, the global biotechnology market size is expected to reach $4 trillion by 2030. The analysts are predicting a compound annual growth rate of close to 14% over the forecast period. Biotechnology startups are acquiring robust funding support and venture capital investments, which, in 2021, amounted to $41 billion, an increase of over 11% as compared to the $36.7 billion raised in the previous year.

Organic factors are driving this growth as well. For example, the British Journal of Cancer predicts that the number of people suffering from cancer in the UK is expected to increase from 2.5 million in 2015 to 4 million by 2030. Per the journal, this would increase the demand for robust and advanced treatment methods for dealing with cancer. The money flowing towards research and development of vaccines has also increased in the past few years, largely as a result of the global panic during the COVID-19 crisis.

Some exciting trends that investors should keep in mind when considering the biotech sector are the advancements being made in relation to the treatment for Alzheimer’s disease. For example, aducanumab, developed by Biogen, is one such candidate. Personalized medicine is also likely to be a strong focus of biotech firms throughout 2022. Furthermore, with the improvements in biotech, the nanobiotechnology segment is expanding at an annual rate of 15% from 2022 to 2030.

Even as investments in the biotech space witness a gradual slowdown due to the shift in focus away from medtech towards other sectors in light of a waning pandemic, the fundamentals of the sector remain robust and the biotechnology sphere remains a key driver of innovation and growth in the economy. A recent Endpoint survey revealed that 66% of investors think that biotech will outperform the broader market in 2022. Nearly 58% plan to increase their exposure to the sector this year in anticipation of this growth.

Our Methodology

The companies that operate in the biotechnology sector and have upcoming products or services with explosive growth potential were selected for the list. The business fundamentals and analyst ratings for the stocks are also discussed to provide readers with some additional insight for their investment decisions. Data from around 900 elite hedge funds tracked by Insider Monkey in the third quarter of 2022 was used to identify the number of hedge funds that hold stakes in each firm.

Photo by National Cancer Institute on Unsplash

Biotech Stocks With The Biggest Upside

10. Alzamend Neuro, Inc. (NASDAQ:ALZN)

Number of Hedge Fund Holders: N/A

Alzamend Neuro, Inc. (NASDAQ:ALZN) is an early clinical-stage biopharmaceutical company that focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. On October 5, Alzamend Neuro, Inc revealed that it has dosed its first healthy adult subject in its Phase IIA multiple ascending dose (“MAD”) study of AL001 in subjects with dementia related to Alzheimer’s.

Among the hedge funds being tracked by Insider Monkey, Chicago-based investment firm Citadel Investment Group is a leading shareholder in Alzamend Neuro, Inc. (NASDAQ:ALZN) with 28,800 shares worth more than $34,000.

Just like Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), Alzamend Neuro, Inc. (NASDAQ:ALZN) is one of the biotech stocks with the biggest upside heading into 2023.

9. Virax Biolabs Group Limited (NASDAQ:VRAX)

Number of Hedge Fund Holders: 1

Virax Biolabs Group Limited (NASDAQ:VRAX) is a biotechnology company that sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. On December 6, Virax Biolabs Group declared that their supplier has received an Emergency Use Authorization from the US FDA for their Over-the-Counter COVID-19 Rapid Antigen Test. The tests are ready for sale in the US by the company.

At the end of the third quarter of 2022, 1 hedge fund in the database of Insider Monkey held stakes worth $115,000 in Virax Biolabs Group Limited (NASDAQ:VRAX).

8. Ampio Pharmaceuticals, Inc. (NYSE:AMPE)

Number of Hedge Fund Holders: 4

Ampio Pharmaceuticals, Inc. (NYSE:AMPE) is a biopharmaceutical company that focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. On March 2, Ampio Pharmaceuticals announced positive data from the modified Intent-to-Treat population in the Company’s AP-013 study, a Phase 3 clinical trial of the company’s lead candidate, Ampion, in patients suffering from severe osteoarthritis of the knee.

Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Millennium Management is a leading shareholder in Ampio Pharmaceuticals, Inc. (NYSE:AMPE) with 2.7 million shares worth more than $163,000.

At the end of the third quarter of 2022, 4 hedge funds in the database of Insider Monkey held stakes worth $204,000 in Ampio Pharmaceuticals, Inc. (NYSE:AMPE), compared to 7 in the preceding quarter worth $581,000.

7. Peak Bio, Inc. (NASDAQ:PKBO)

Number of Hedge Fund Holders: 5

Peak Bio, Inc. (NASDAQ:PKBO) is a clinical-stage biopharmaceutical company that focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. On November 4, Ladenburg Thalmann analyst Ahu Demir initiated coverage of PeakBio, Inc. (NASDAQ:PKBO) stock with a Buy rating and $15 price target, noting that the company’s lead asset is PHP-303, a 5th-generation neutrophil elastase inhibitor that is Phase 2-ready and will be evaluated in a Phase 2 study for alpha-1 antitrypsin deficient illness.

Among the hedge funds being tracked by Insider Monkey, Washington-based firm Deerfield Management is a leading shareholder in Peak Bio, Inc. (NASDAQ:PKBO) with 725,000 shares worth more than $7.2 million.

6. Genmab A/S (NASDAQ:GMAB)

Number of Hedge Fund Holders: 12

Genmab A/S (NASDAQ:GMAB) develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. In late October, the company announced worldwide net trade sales of $2.05 billion for Darzalex (daratumumab), an anti-cancer monoclonal antibody medication, for the third quarter of 2022, compared with $1.99 billion generated in the previous quarter. The net trade sales were $1.09 billion in the US and $955 million in the rest of the world.

On November 14, JPMorgan analyst James Gordon maintained an Overweight rating on Genmab A/S (NASDAQ:GMAB) stock and raised the price target to DKK 3,450 from DKK 2,900.

At the end of the third quarter of 2022, 12 hedge funds in the database of Insider Monkey held stakes worth $125 million in Genmab A/S (NASDAQ:GMAB), compared to 6 in the preceding quarter worth $96.4 million.

Among the hedge funds being tracked by Insider Monkey, Boston-based firm Arrowstreet Capital is a leading shareholder in Genmab A/S (NASDAQ:GMAB) with 1.4 million shares worth more than $47 million.

In addition to Pfizer Inc. (NYSE:PFE), Eli Lilly and Company (NYSE:LLY), and AbbVie Inc. (NYSE:ABBV), Genmab A/S (NASDAQ:GMAB) is one of the biotech stocks with the biggest upside heading into 2023.

In its Q2 2021 investor letter, Artisan Partners, an asset management firm, highlighted a few stocks and Genmab A/S (NASDAQ:GMAB) was one of them. Here is what the fund said:

“Genmab A/S (NASDAQ:GMAB) is a creator and developer of human antibody products for the treatment of life-threatening and debilitating diseases. Shares have been volatile this year amid a binding arbitration with Johnson & Johnson to decide key aspects of royalty payments related to nextgeneration multiple myeloma drug, Darzalex FASPROTM. Last quarter, we indicated share weakness in February and early March seemed to overstate the potential negative outcome, especially relative to the additional growth opportunities within Genmab’s promising R&D pipeline. That potential was on display in Q2 when the company reported positive data for its bispecific antibody Epcoritamab, a new drug being developed with AbbVie to treat lymphoma. Bispecific antibodies are recombinant antibodies aimed at two biological targets simultaneously and are an important emerging technology area. The company expects to report further clinical trial updates later this year for another bispecific antibody it has developed with partner BioNTech. This new drug is expected to treat patients with metastatic or unresectable malignant solid tumors who are not candidates for standard therapy. We believe Genmab is establishing itself as one of the clear leaders in bispecifics, which increases our optimism about the long-term value of the company’s R&D platform.”

Click to continue reading and see 5 Biotech Stocks With The Biggest Upside.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on May 7, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months

• BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.

• One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Content: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on January 7, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up